Can Endometrial Cancer Come Back After Total Hysterectomy?

Endometrial cancer can return after a total hysterectomy, though the overall risk for early-stage disease is relatively low. In a large study of women with stage I endometrial cancer, about 10% experienced a recurrence, with isolated vaginal recurrences accounting for roughly 2% and the remaining 8% involving sites beyond the vagina, such as lymph nodes, lungs, or the peritoneum. The risk depends heavily on the original tumor’s features, and medical science has become much more precise at identifying who faces higher danger and who can breathe a little easier.

Where Recurrence Tends to Show Up

After hysterectomy, the vaginal cuff (the closed top of the vagina where the cervix once was) is the most common local site for cancer to reappear. Among women who developed an isolated vaginal recurrence in one large cohort, about 69% of those recurrences were at the vaginal apex specifically. This is thought to happen because microscopic cancer cells can be left behind in the surrounding tissue despite what appears to be a complete removal of the uterus.¹ In rare cases, residual dormant tumor cells can linger for years before reactivating. One documented case report describes a vaginal recurrence more than 17 years after the original hysterectomy and adjuvant radiation, suggesting that some cancer cells can enter a kind of prolonged dormancy before growing again.²

Distant recurrence is a different picture. The lung is the most common site when endometrial cancer spreads beyond the pelvis, accounting for roughly 43% of exclusive first distant metastases in one multicenter study.³ Other typical distant sites include pelvic and para-aortic lymph nodes and the peritoneum. Less common but still documented locations include the liver, bones, brain, and adrenal glands.⁴ Among these rarer sites, brain metastasis carries the worst prognosis, with a median survival of only about five months.⁵

When Recurrence Happens

Most recurrences are detected within the first few years after surgery. Across molecular subtypes, the overall median time to first recurrence is around 16 months.⁶ Local vaginal recurrences tend to appear sooner than distant ones. In women with stage I disease, the median time to an isolated vaginal recurrence was 11 months, compared with 20 months for extravaginal recurrence.¹ Among distant sites, brain metastases tend to appear fastest (median around 7 months from treatment completion), while bone metastases take longer to emerge (median around 19 months).³

This timeline matters because it shapes how closely doctors monitor you in the years following surgery. But the 17-year case report mentioned earlier is a reminder that late recurrences, while uncommon, are not impossible. Surveillance remains relevant even after you cross the five-year mark.

What Makes Recurrence More or Less Likely

Not all endometrial cancers carry the same recurrence risk. Several features of the original tumor are strong predictors, and understanding them helps explain why one person’s outlook after hysterectomy is very different from another’s.

Tumor Type and Grade

The most common form of endometrial cancer, endometrioid type, tends to have a better prognosis, especially when it is low-grade. The aggressive histological subtypes tell a different story. Clear cell carcinoma has a five-year relapse rate of about 50%.⁷ Uterine carcinosarcoma carries an even higher risk of death compared with serous or clear cell subtypes, even when caught at an early stage.⁸ These aggressive subtypes are less common, but if your pathology report mentions serous, clear cell, or carcinosarcoma histology, your doctors will typically recommend more aggressive adjuvant treatment and closer follow-up.

Molecular Subtype

Beyond what the tumor looks like under a microscope, its molecular characteristics have become central to predicting recurrence. The four recognized molecular classes sort endometrial cancers into meaningfully different risk categories. Tumors with a POLE mutation have the best outlook: in one study of 265 surgically treated patients, those with POLE-mutated tumors had a 100% five-year recurrence-free survival rate, even when diagnosed at advanced stages.⁹ Tumors with mismatch repair deficiency (dMMR) or no specific molecular profile fall into an intermediate-risk group. At the opposite end, tumors with abnormal p53 have the worst outcomes, with a five-year recurrence rate of about 23% even in cases without myometrial invasion, compared to 0% for p53-normal tumors in the same study.¹⁰

Among patients with dMMR tumors, the median time to recurrence is the shortest at about 13 months, which is relevant because this subtype also responds especially well to immunotherapy when recurrence does occur.⁶

Lymphovascular Space Invasion

If pathology shows that cancer cells had invaded the blood or lymph vessels in and around the tumor before surgery, the risk of recurrence goes up meaningfully. In a large multicenter study of early-stage endometrial cancer, lymphovascular space invasion (LVSI) was an independent risk factor for both shorter disease-free survival and distant recurrence, nearly doubling the hazard for both outcomes.¹¹ The extent matters, too. Substantial LVSI in molecular subtypes that are otherwise considered intermediate risk can dramatically increase the hazard of recurrence.¹²

How Adjuvant Treatment Reduces the Risk

For many women with early-stage disease, surgery alone is sufficient. But when pathological features suggest a higher risk of recurrence, additional treatment after hysterectomy can cut that risk substantially.

Vaginal brachytherapy, a form of internal radiation delivered to the top of the vagina, is the most common adjuvant treatment for intermediate-risk early-stage disease. It keeps vaginal recurrence rates extremely low, in the range of 0% to about 3%, with relatively mild side effects that are mostly limited to vaginal dryness or shortening.¹³ This tracks with the PORTEC-2 trial’s finding that brachytherapy alone performs as well as whole-pelvis external radiation for preventing vaginal recurrence in this group, with fewer side effects.

For higher-risk patients (advanced stage, aggressive histology), the conversation shifts toward combining chemotherapy with radiation. The landmark PORTEC-3 trial found that adding chemotherapy to radiation reduced the five-year rate of distant metastasis from about 29% to about 21%.¹⁴ An important nuance, though: radiation is most effective at controlling local and regional disease, while chemotherapy targets distant spread. In a comparison of chemoradiotherapy versus chemotherapy alone, chemoradiotherapy cut vaginal recurrence from 7% to 2% and pelvic node recurrence from 20% to 11%, but distant recurrence was actually slightly more common in the chemoradiotherapy arm.¹⁵ The general takeaway is that radiation and chemotherapy address different pieces of the recurrence puzzle, and many higher-risk patients benefit from both.

Symptoms That Should Prompt a Call to Your Doctor

Most recurrences are caught because the patient notices something wrong, not because a routine scan picks it up. In a large cohort of women with early-stage disease who recurred, about two-thirds were symptomatic at the time of detection.¹⁶ Vaginal bleeding is the classic warning sign for vaginal cuff recurrence, but pain has emerged as the most common symptom overall across all recurrence types in more recent data.¹⁷

A study that tested a structured symptom checklist during nurse-led follow-up calls found that back or lumbar pain, vaginal bleeding, and persistent fatigue were each significantly associated with recurrence.¹⁸ None of these symptoms alone proves that cancer has returned; they are common after treatment for many reasons. But their combination, or their persistence when they should be improving, warrants investigation. Patients whose recurrences are detected while they are still asymptomatic tend to have significantly better three-year survival than those who present with symptoms.¹⁶

What Follow-Up Looks Like After Hysterectomy

Surveillance schedules are tailored to how aggressive the original cancer was. The Society of Gynecologic Oncology (SGO) recommends that women with low-risk, early-stage disease (stage IA, grade 1 or 2) be seen every six months for the first year, then annually. Intermediate-risk patients are seen every three months in the first year, then every six months through year five, then annually. Those with the highest-risk features (stage III–IV, or serous or clear cell histology) are seen every three months for two years, every six months for three more years, and then annually.¹⁹

These visits center on a physical examination, including a pelvic exam. Interestingly, routine imaging and blood tests like CA-125 are not generally recommended for asymptomatic women. Physical examination has been reported as more effective than vaginal cytology, lab testing, or imaging for detecting recurrence in the absence of symptoms. CT or PET scans come into play when symptoms or exam findings raise a suspicion.¹⁹

Treating Recurrence When It Happens

The approach to treating recurrent endometrial cancer depends on where it shows up and what treatment the patient already received. A vaginal cuff recurrence in someone who never had radiation is often very treatable with radiation therapy, and cure rates for this scenario are encouraging. Salvage brachytherapy can be effective even in unusual cases, including the 17-year-late recurrence described earlier, where the patient was successfully treated.

For regional recurrences in the pelvis or peritoneal cavity, a combination approach that includes surgery, radiation, and chemotherapy appears to offer the best chance. In one small institutional series, patients who received this multimodality treatment had a two-year progression-free survival of about 62%, and they were the only patients still alive at 40 months of follow-up.²⁰ This is a small study, so the numbers carry uncertainty, but the direction is consistent with broader clinical experience: aggressive combined treatment gives the best shot at long-term control for localized recurrences.

For advanced or distant recurrence, immunotherapy has changed the landscape. In a major trial, adding the immune checkpoint inhibitor dostarlimab to chemotherapy produced a two-year progression-free survival of about 61% in patients with mismatch repair-deficient tumors, compared to roughly 16% with chemotherapy and placebo.²¹ Even across all molecular subtypes combined, the combination improved two-year overall survival from 56% to 71%. This represents a genuine shift in how recurrent endometrial cancer is managed, particularly for the dMMR subgroup.

Circulating Tumor DNA as an Early Warning

One of the more promising developments in recurrence detection is the use of circulating tumor DNA (ctDNA), tiny fragments of tumor genetic material that can be found in a blood draw. In a study of patients with stage I uterine cancers, those who had detectable ctDNA after surgery had a recurrence rate of about 52%, compared to 0% in patients whose ctDNA was undetectable on follow-up testing. Post-surgical ctDNA status was the only factor that remained a significant predictor of recurrence after adjusting for all the standard pathological risk features like histology, mismatch repair status, and p53.²²

This technology is not yet ready for routine clinical use. A recent meta-analysis of 11 studies covering nearly 1,300 patients confirmed that postoperative ctDNA positivity does predict worse outcomes, but the various research groups used different laboratory methods, and independent validation is still limited.²³ Still, the signal is strong enough that many oncologists expect ctDNA testing will eventually become a standard part of post-surgical monitoring, potentially identifying women who need additional treatment before any visible recurrence appears on imaging.

Body Weight and Recurrence Risk

Obesity is a well-known risk factor for developing endometrial cancer in the first place, but weight changes after treatment also seem to matter for recurrence. In women with endometrioid-type tumors specifically, those who recurred had gained more weight after surgery (a mean BMI increase of about 1.9 points) compared to those who remained disease-free (a mean increase of about 0.5 points). On multivariate analysis, BMI change was independently associated with recurrence risk.²⁴ This association was not significant for non-endometrioid histologies, suggesting the metabolic and hormonal pathways linked to obesity play a more prominent role in the endometrioid subtype. It is a single study and not proof that weight management prevents recurrence, but it adds to a growing body of evidence that maintaining a stable weight after treatment is a reasonable and potentially modifiable goal.

Hormone Replacement Therapy After Endometrial Cancer

Surgical menopause from hysterectomy (particularly with removal of the ovaries) brings hot flashes, sleep disruption, bone loss, and other menopausal symptoms, often suddenly and severely. Many women understandably want to know whether hormone replacement therapy (HRT) is safe. A Cochrane systematic review found that in the only available randomized trial, recurrence occurred in about 2.3% of women taking estrogen compared with 1.9% taking placebo, a difference that was not statistically significant.²⁵ The review concluded that neither the trial nor the broader non-randomized evidence suggested significant harm from HRT after early-stage endometrial cancer treatment, though the certainty of evidence was rated as very low. In practice, this means HRT is not categorically off the table for survivors of early-stage disease, but it should be a careful, individualized discussion with your oncologist, especially if your tumor had aggressive features or was estrogen-receptor-positive.

The Fear of Recurrence

The emotional weight of a cancer diagnosis does not end with surgery. Fear of cancer recurrence is common and persistent among endometrial cancer survivors. In a large study of older survivors of several cancer types enrolled in the Women’s Health Initiative, about 16% reported high levels of fear of recurrence, with no significant differences between breast, ovarian, endometrial, and colorectal cancer survivors. Being younger at diagnosis, reporting more physical symptoms, having received chemotherapy, and rating your overall health as lower were all associated with higher fear levels.²⁶ This is worth knowing not because it changes medical management, but because it validates a feeling that many survivors carry silently. If anxiety about recurrence is affecting your quality of life, it is a legitimate reason to bring it up with your healthcare team, and structured survivorship programs increasingly include psychological support for exactly this reason.

Sentinel Lymph Node Mapping and Recurrence Patterns

How surgeons stage the cancer at the time of hysterectomy can influence where recurrence shows up later. Sentinel lymph node (SLN) mapping, which involves injecting a tracer to identify the first lymph nodes draining the tumor and removing only those, has become increasingly common as an alternative to removing large groups of lymph nodes. A comparison of the two approaches found no significant difference in overall recurrence-free survival at four years. But the pattern of recurrence shifted: in the SLN group, pelvic sidewall recurrences accounted for 30% of all recurrences, compared to over 71% in the broader lymph node dissection group.²⁷ The interpretation is that SLN mapping, by more precisely identifying affected nodes (including through ultrastaging techniques), allows for better-targeted adjuvant therapy, which reduces local recurrences where they are most likely to occur. Fewer pelvic sidewall recurrences means the approach may actually improve regional control even while being less invasive than traditional node dissection.

1
PubMed Central. Isolated vaginal recurrence in women with stage I endometrial cancer
2
PubMed Central. Vaginal Recurrence More than 17 Years after Hysterectomy and Adjuvant Treatment for Uterine Carcinoma with Successful Salvage Brachytherapy: A Case Report
3
PubMed. Incidence, patterns and prognosis of first distant recurrence after surgically treated early stage endometrial cancer: Results from the multicentre FRANCOGYN study group
4
PubMed Central. Typical and atypical metastatic sites of recurrent endometrial carcinoma
5
PubMed. Clinicopathological study of organ metastasis in endometrial cancer
6
PubMed. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification
7
PubMed Central. Factors That Affect Survival Outcomes in Patients with Endometrial Clear Cell Carcinoma
8
PubMed Central. Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta‐analysis of survival
9
British Journal of Cancer. Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer
10
PubMed Central. Impact of p53 status on recurrence patterns and oncologic outcomes in non-invasive high-grade endometrial cancer
11
PubMed Central. Lymphovascular Space Invasion in Early-Stage Endometrial Cancer (LySEC): Patterns of Recurrence and Predictors. A Multicentre Retrospective Cohort Study of the Spain Gynecologic Oncology Group
12
International Journal of Gynecological Cancer. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer
13
PubMed Central. American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review
14
The Lancet Oncology. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
15
PubMed Central. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
16
PubMed. Detection of recurrence in early stage endometrial cancer – the role of symptoms and routine follow-up
17
PubMed. The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?
18
PubMed Central. Can a symptom checklist improve the triage of patients following successful endometrial cancer treatment?
19
PubMed Central. Surveillance and Care of the Gynecologic Cancer Survivor
20
PubMed Central. Salvage treatment in recurrent endometrial cancer of the pelvis and peritoneal cavity
21
PubMed. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
22
PubMed. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies
23
PubMed Central. Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers: Molecular Rationale, Clinical Evidence, and Translational Barriers
24
International Journal of Gynecological Cancer. Effect of BMI change on recurrence risk in patients with endometrial cancer
25
PubMed Central. Hormone replacement therapy for women previously treated for endometrial cancer
26
PubMed Central. Fear of recurrence among older breast, ovarian, endometrial, and colorectal cancer survivors: Findings from the WHI LILAC study
27
PubMed. Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer